Your Article Summary
See Latest ArticlesChanges in Vitamin E Prescribing for Alzheimer Patients
American Journal of Geriatric Psychiatry, 06/24/09
Dysken MW et al. - AAGP members significantly reduced prescribing Vitamin E to patients with Alzheimer disease after 2005. The two reports are discussed with an emphasis on their methodological limitations and the potential for additional information on Vitamin E side effects from ongoing research.
Methods- A three-item questionnaire was mailed to all AAGP members who had prescription privileges to assess changes in prescribing Vitamin E after January, 2005.
- A total of 572 completed surveys were returned for a response rate of 35%.
- Nearly 60% of respondents reported a change over the 2 years that followed the 2005 reports.
- The greatest change was in the group not prescribing Vitamin E, which increased from 6.6% before 2005 to 60.6% afterward.
Today in Geriatric Psych...keeping you current
Receive free subspecialty "5-minute updates" via email
Management of agitation and aggression associated with Alzheimers disease: controversies and possible solutions
Current Opinion in Psychiatry, 10/12/09
What is the association between depression and Alzheimer's disease?
Expert Review of Neurotherapeutics, 11/19/09
The Occurence of Mood and Anxiety Disorders in Heart Transplant Recipients
Transplantation Proceedings, 11/02/09
Today in Neuropsych Sciences...keeping you current
Receive free subspecialty "5-minute updates" via email
Impulsivity, personality and bipolar disorder
European Psychiatry , 11/06/09
The role of dopamine in bipolar disorder
Bipolar Disorders, 11/18/09
Serum brain-derived neurotrophic factor in bipolar and unipolar depression: A potential adjunctive tool for differential diagnosis
Journal of Psychiatric Research, 11/20/09
Today in Personality Disorders...keeping you current
Receive free subspecialty "5-minute updates" via email
Impulsivity, personality and bipolar disorder
European Psychiatry , 11/06/09
Estimation of clonazepam abuse liability: a new method using a reimbursed drug database
International Clinical Psychopharmacology, 10/20/09
Open-label study of high (30 mg) and moderate (20 mg) dose escitalopram for the treatment of obsessive-compulsive disorder
International Clinical Psychopharmacology, 10/23/09